Admedus : Represented at Leading US Heart Conferences

da0db9ea-4798-4b7d-8c01-cf7dfd28f349.pdf

Admedus Ltd

ABN 35 088 221 078

COMPANY ANNOUNCEMENT

REGISTERED OFFICE:

26 Harris Road MalagaWestern Australia6090

PO Box 6879

East PerthWestern Australia 6892

T [phone]

F [phone]

[e-mail] www.admedus.com

ADMEDUS REPRESENTED AT LEADING US HEART CONFERENCES

• Admedus represented at leading US cardiovascular heart conferences - AATS Aortic Symposium 2016 and AATS Annual Meeting 2016

• Admedus to host US investor day in New York City on Wednesday, 11 May 2016 on the future of valve repair

Brisbane, Australia 11th of May 2016

Admedus has today announced that in line with the Company's focus on driving sales of its lead regenerative tissue product CardioCel® in the valve repair market, it will be attending leading US cardiovascular conferences - the American Association for Thoracic Surgery (AATS) Aortic Symposium 2016 May 12-13 in New York, and the 96th AATS Annual Meeting taking place from 14 - 18 May in Baltimore, Maryland.

"CardioCel is fast becoming the surgeon-preferred material for reconstruction and repairs in the aortic and mitral valve repair market, with the product providing a genuine alternative for patients compared to bio-prosthetic valves. We believe CardioCel represents a disruptive technology and we are concentrating on building awareness of our product in this market," said Admedus Managing Director, Mr Lee Rodne.

The two conferences, together known as AATS Week, bring together the world's foremost scientists and medical professionals in the field of cardiothoracic surgery and provide seven days of intensive instruction and state-of-the art information on the latest developments in the field. Admedus can be found at booth T08 at the AATS Symposium in New York and booth 411 at the AATS Annual Meeting in Baltimore.

Prior to the AATS Symposium in New York, Admedus will be hosting a "Meet the Surgeon" investor day on Wednesday, 11 May to discuss the future of valve repair and to share knowledge on using CardioCel for mitral and aortic valve repair and reconstructions.

The global market for cardiovascular disease is estimated to grow to USD $4.8 billion by 2020. In the United States, surgeons currently perform approximately 106,000 heart valve operations each year.

"Admedus is focused on continuing to show the utility and benefits of CardioCel to patients and surgeons in the multibillion dollar heart valve market, expanding the use of CardioCel in the adult valve market and driving CardioCel sales globally," added Mr Rodne.

Admedus continues to progress its aortic valve reconstruction post-market study with several centres globally recruiting patients. An update on the study is anticipated in the coming months. The study is designed to further show the use of CardioCel in repairing aortic heart valves and its potential for improved patient outcomes compared to bio- prosthetic valves.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus Website: www.admedus.com

Blog: www.admedus.com/au/category/news/

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: [phone]

Media:

Shevaun Cooper | PR Manager | Admedus Limited

Tel: [phone] | Email: [e-mail]

Media Europe

FTI Consulting

Simon Conway / Victoria Foster Mitchell Tel: [phone]

[e-mail]

US Investor

Rx Communications Group, LLC Melody A. Carey

[phone]

[e-mail]

About CardioCel®

CardioCel is a type of cardiovascular bio-scaffold that can be used to repair congenital heart deformities and more complex heart defects. It is used to repair diseased paediatric and adult hearts. These repairs range from routine hole-in-the-heart operations to major vessel outflow tract repairs. The CardioCel scaffold may also be used to repair heart valves. CardioCel has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration, suggesting that the product facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue. CardioCel is the Admedus Group's lead regenerative tissue bio-scoffold. It is engineered via the Admedus Group's proprietary ADAPT™ tissue engineering process to produce a durable, collagen scaffold with handling properties preferred by surgeons that avoids calcification, while supporting native cell infiltration, growth and differentiation. CardioCel is a registered trademark.

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com